MTOR and non-small cell lung carcinoma: NVP-BEZ235, a novel dual inhibitor of PI3K and mTOR, was highly active in all NSCLC cell lines tested with IC50s in the nanomolar range and led to downregulation of pAKT and pP70S6K.